Stockscreener 앱 받기
1.20
2.56%
0.03
Soligenix Inc 주식(SNGX)의 최신 뉴스
Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - NewMediaWire
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - TradingView
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting - Benzinga
Soligenix (SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - NewMediaWire
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - Benzinga
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - Nasdaq
HyBryte Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - Bitget
Soligenix (SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication - NewMediaWire
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication - Digital Journal
Soligenix (SNGX) Highlights HyBryte's Promise in Treating Early-Stage CTCL - GuruFocus
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times
IBN Announces Latest Episode of The BioMedWire Podcast - GlobeNewswire
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" - ChartMill
Soligenix's HyBryte Clinical Data Published in Peer-Reviewed Journal, Supporting Potential as First-Line CTCL Treatment - citybuzz -
Soligenix Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Total debt per share of Soligenix, Inc. – LSE:0A6I - TradingView
Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease - USA Today
Earnings Risk: Should you avoid Soligenix Inc stock right now2026 Trends & Verified Chart Pattern Signals - baoquankhu1.vn
SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Smartkarma
Soligenix receives UK regulatory designation for Behçet’s drug By Investing.com - Investing.com Canada
Soligenix (SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behcet Disease - NewMediaWire
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency - Lelezard
Soligenix receives UK regulatory designation for Behçet’s drug - Investing.com
Soligenix (SNGX) Receives UK Nod for Innovative Behcet's Disease Treatment - GuruFocus
Soligenix Announces SGX945 Receives Promising Innovative Medicin - GuruFocus
Soligenix (SNGX) Leverages Platform Science for Broader Therapeutic Reach - NewMediaWire
Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach - TradingView
SNGX SEC FilingsSoligenix Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SNGX Earnings History & Surprises | EPS & Revenue Results | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
SNGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behcet Disease - Digital Journal
Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit - Digital Journal
Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - Digital Journal
Analysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Soligenix (SNGX) and Day One Biopharmaceuticals (DAWN) - The Globe and Mail
Soligenix receives positive EMA opinion for orphan drug status - Investing.com Australia
Biopharmaceutical company Soligenix, Inc. recently announced that its application for orphan drug designation for SGX945, developed for the treatment of Behçet's Disease, has received a positive opinion from the European Medicines Agency (EMA). - Bitget
Soligenix receives positive EMA opinion for orphan drug status By Investing.com - Investing.com UK
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease - Nasdaq
Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease - The Globe and Mail
SNGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Growth Value: Is Soligenix Inc a speculative investmentOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Soligenix to Present at BIO Investment Summit - Intellectia AI
Soligenix to Present at BIO Investment & Growth Summit - PR Newswire
SNGX PE Ratio & Valuation, Is SNGX Overvalued - Intellectia AI
Will Soligenix Inc. face regulatory challenges2025 Stock Rankings & Proven Capital Preservation Methods - mfd.ru
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Armistice Capital and Steven Boyd report 4.99% stake in Soligenix (SNGX) - Stock Titan
Why Soligenix Inc. stock is favored by top institutions2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru
Soligenix, Inc. Announces Adjournment of Annual Meeting, Informa - GuruFocus
Will Soligenix Inc. stock split attract more investors2025 Geopolitical Influence & AI Forecasted Stock Moves - mfd.ru
Analysts Offer Insights on Healthcare Companies: Soligenix (SNGX) and Boston Scientific (BSX) - The Globe and Mail
Soligenix Provides Shareholder Update on Rare Disease Pipeline - TipRanks
1.82%
자본화:
|
볼륨(24시간):